Largest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
List view / Grid view
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
Researchers have developed a new form of immunotherapy that could provide a longer life expectancy to men with prostate cancer.
Researchers utilised AI to identify genes that reprogramme GBM cancer cells into dendritic cells within the tumour.
The study’s results indicate that spatial sequencing of mixed-type breast cancers could inform personalised treatment.
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.